#Ribonucleic Acid (RNA) Therapeutics Market demand

[shivt123]

Ribonucleic Acid (RNA) Therapeutics Market

[sandlerresearch]

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) published on

https://www.sandlerresearch.org/hepatitis-c-tests-in-vitro-diagnostics-global-market-analysis-and-forecast-model-covid-19-market-impact.html

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Summary

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby.

Diagnosis of HCV infection can be done by screening for anti-HCV antibodies along with a serological test to confirm the viral infection. Nucleic acid test for HCV ribonucleic acid (RNA) is performed in case of positive test results for anti HCV antibodies to confirm chronic infection. Since there is no vaccine available for HCV infection, the World Health Organization (WHO) recommends blood tests to screen patients that are at an increased risk of HCV infection and reducing the risk of HCV exposure in health care settings.

Screening of pregnant women for HCV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby. The HCV tests include EIA, NAAT and multi parameter NAAT HCV tests.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are –

Currently marketed Hepatitis C Tests and evolving competitive landscape – – Insightful review of the key industry trends. – Annualized total Hepatitis C Tests market revenue by segment and market outlooks from 2015-2030. – Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights – – Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market. – SWOT analysis for Hepatitis C Tests market. – Competitive dynamics insights and trends provided for Hepatitis C Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape. – Country specific overview of the healthcare system. – Country specific reimbursement policies. – Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories , Siemens Healthineers AG, F. Hoffmann-La Roche Ltd , Ortho-Clinical Diagnostics Inc , Hologic Inc and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for – – CMO executives who must have deep understanding of the Hepatitis C Tests market place to make strategic planning and investment decisions. – Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. – Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to – – Understand the impact of COVID-19 on Hepatitis C Tests market. – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving Hepatitis C Tests. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis C Tests market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track device sales in the global and country-specific Hepatitis C Tests market from 2015-2030. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[millionmarketresarch-blog]

Antisense & RNAi Therapeutics Market To Witness Enhanced Growth Owing To Rising Demand From Pharmaceuticals Industry Till 2025

03th July 2019: Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Get a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of advantages of the technology over antisense technology. The miRNA maintains the cells identity; whereas siRNA allows induction at enhanced stages of cancer growth.

The mode of action comprises of topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because liver can be targeted easily by virtue of an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years.

Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be growing number of clinical trials, government initiative for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for development of RNAi therapeutic. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as presence of key manufacturers in the region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise government initiative toward R&D and various other forms of siRNA delivery techniques is a strong factor.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market 

The key players of Antisense & RNAi Therapeutics industry are Benitec Biopharma, GSK, Marina Biosciences, Sanofi-Genzyme, and Alnylam Pharmaceuticals. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Market Segment:

Antisense & RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025)

   • RNA Interference

       • siRNA

       • miRNA

   • Antisense RNA

Antisense & RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)

   • Oncology

   • Cardiovascular

   • Respiratory Disorders

   • Renal Diseases

   • Neurodegenerative Disorders

   • Genetic Disorders

   • Infectious Diseases

   • Other

Antisense & RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

   • Pulmonary Delivery

   • Intravenous Injections

   • Intradermal Injections

   • Intraperitoneal Injections

   • Topical Delivery

   • Other Delivery Methods

Antisense & RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

   • North America

       • U.S.

       • Canada

   • Europe

       • Germany

       • U.K.

   • Asia Pacific

       • Japan

       • China

   • Latin America

       • Brazil

   • Middle East & Africa

       • South Africa

For More Information visit https://millioninsightsresearch.blogspot.com

[sandlerresearch]

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 published on

http://www.sandlerresearch.org/hemophilia-a-and-b-global-drug-forecast-and-market-analysis-to-2028.html

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Summary

Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care.

Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing antibodies, or inhibitors, against replacement factors. Overall, the late-stage pipeline indicates an increase in the development of alternative coagulation promoters (ACPs) and gene therapies to further target these areas of significant unmet need. During the forecast window, Roche entered the market with the first monoclonal antibody targeting hemophilia A patients both with and without inhibitors, which addresses the unmet needs of frequency and route of administration. Sanofi are also to exploring a non-replacement approach and will enter the market with the ribonucleic acid (RNA) therapeutic, Fitusiran (previously Alnylam’s), further ensuring cross-segment efficacy in patients both with and without inhibitors. The approval of these new products has begun to have a drastic effect on the hemophilia A and B treatment landscapes which is expected to continue through the forecast window. During this forecast window, several pharmaceutical companies, including BioMarin, uniQure and Pfizer/Roche (Spark Therapeutics), will also be launching new gene therapies that aim to cure, or at least reduce the severity of, hemophilia A and B and diminish inhibitors. If approved, gene therapies will pose a threat to existing hemophilia therapies.

GlobalData projects the global hemophilia A and B marketplace to experience a significant growth during the forecast period. GlobalData valued the hemophilia A and B market at $6.9B in 2018 in the 8MM and expects the market to increase to $9.3B in 2028 at a Compound Annual Growth Rate (CAGR) of 2.9%. This growth will be driven primarily by the increasing prophylactic treatment rates among patients, the continued use of recombinant products and the uptake of non-replacement therapies in the 8MM. However, cost constraints in the 8MM are expected to limit the premium pricing opportunities for new products such as late-to-market long-acting factor concentrates and new alternative coagulation promoters, thereby limiting the size of the hemophilia market.

This model covers the market forecast for marketed and late-stage pipeline hemophilia A and B therapeutics. The base year of this model is 2018, and the forecast period is 2018-2028.

Key Questions Answered

– Which pipeline agents – replacement factors, alternative coagulation promoters and gene therapies – are the most promising and expected to launch in the 8MM? – What are the forecasted sales of these agents and what will be their impact in the hemophilia A and B market? – What are the main unmet needs in hemophilia A and B, and which pipeline drugs will fulfil these needs, and to what extent? – What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy? – Key Opinions Leader (KOL) and payer insights across the 8MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Key Highlights

– The hemophilia A & B market is expected to grow at a CAGR of 2.9% until 2028, reaching a global value of $9.3B. – GlobalData forecasts a marginal increase in prevalence rates across 8MM with AGR of 0.1% due to increased in prevalence rates across the US, Spain and UK. – Gene therapies will emerge as novel treatments for hemophilia A & B during the forecast period. Particularly, BioMarin’s first-to-market gene therapy, ValRox is likely to perform exceptionally well. Additionally, Roche’s Hemlibra is anticipated to achieve blockbuster status by the end of the forecast period. – Rising life expectancy for hemophilia patients leads to an increase in the size of the treated population. – Expected launches of expensive new drugs such as gene therapies, continued preference for prophylactic regimens, continued patient evolution from plasma-based to recombinant therapies are other significant drivers of market. – Limited scope for price premiums of late-to-market replacement products, high uptake of lower-priced drugs, rise in cost-consciousness and imposing market access barriers for the entry of expensive gene therapies are expected to affect market growth negatively. – Level of unmet needs in hemophilia patients is high but is expected to decrease due to advances in treatments and the introduction of novel therapies. – There are major market opportunities for the development of novel therapies, cheaper therapies for prophylaxis treatment, more effective treatments for hemophilia B patients with inhibitors and more therapies with convenient administration routes.

Scope

Overview of hemophilia A and B, including – – Disease overview – etiology, pathophysiology, symptoms, prognosis and quality of life – Epidemiology – Disease management – diagnosis and treatment Patient segmentation – – Mild, Moderate, and Severe – Hemophilia A and B with and without inhibitors – Males and Females – All ages, Pediatrics and Adults Annualized hemophilia A and B therapeutics market revenue and treatment usage patterns – – Patient shares and number of patients treated for marketed and pipeline products – Duration of and, daily and annual cost of therapies per patient – Product sales by usage and total sales of marketed and pipeline products

Key topics covered include –

– Competitive assessment of marketed and pipeline products including SWOTs and, clinical and commercial positioning. – Unmet needs and opportunities including current and future level of attainment and gap analysis – Pipeline assessment – analysis of commercial and clinical attributes of promising drugs in clinical development and comprehensive analysis of promising approaches and emerging trends in early stage development – Analysis of the current and future players for the global hemophilia A and B market, including strength of marketed and pipeline products and trends in corporate strategy, profiles of leading companies in the hemophilia market. – Market outlook of the 8MM including forecast, key events and, market drivers and barriers.

Reasons to buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[sandlerresearch]

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model published on

http://www.sandlerresearch.org/hepatitis-c-tests-in-vitro-diagnostics-global-market-analysis-and-forecast-model.html

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Summary

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Hepatitis C is a viral infection caused by Hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby. Diagnosis of HCV infection can be done by screening for anti-HCV antibodies along with a serological test to confirm the viral infection. Nucleic Acid Test for HCV Ribonucleic Acid (RNA) is often performed in cases to confirm chronic infection.

The World Health Organization estimates that 71 million people are living with chronic hepatitis C infection globally. Disease incidence and prevalence are not the only factors influencing the Hepatitis C Tests market. Sales of these devices are also heavily impacted by fluctuations in the number of pregnant women, semen donations, whole blood donations, and source plasma donations.

The predominant devices used for Hepatitis C detection are enzyme immunoassay (EIA) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. EIA Hepatitis C devices are used for disease diagnosis as well as screening of whole blood, source plasma, and sperm donations as well as for pregnant women screening. Nucleic Acid Amplification (NAAT) tests are sometimes used as confirmatory tests for samples that have already tested positive for HCV through EIA. NAAT are also used for serial monitoring of Hepatitis C patients, to aid in management of the disease and to inform treatment strategies i.e. with anti-retroviral agents.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market Model

Currently marketed Hepatitis C Tests and evolving competitive landscape – – Insightful review of the key industry trends. – Annualized total Hepatitis C Tests market revenue by segment and market outlooks from 2015-2028. – Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights – – Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market. – SWOT analysis for the market. – Competitive dynamics insights and trends provided for the overall market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape. – Country specific overview of the healthcare system. – Country specific reimbursement policies. – Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Ortho-Clinical Diagnostics Inc, Bio Manguinhos and Fiocruz, Grifols, S.A, F. Hoffmann-La Roche Ltd (Roche Diagnostics International Ltd), Siemens Healthineers AG, Qiagen NV, bioMerieux SA, DiaSorin S.p.A., United States Biological, SeraCare Life Sciences, Inc., ThermoFisher Scientific and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for – – CMO executives who must have deep understanding of the Hepatitis C Tests marketplace to make strategic planning and investment decisions. – Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. – Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

The model will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving Hepatitis C Tests market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis C Tests market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Track device sales in the global and country-specific Hepatitis C Tests market from 2015-2028. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.